Cerebrospinal fluid light and heavy neurofilament level increased in anti-N-methyl-D-aspartate receptor encephalitis

Jiayu Li¹,² | Yong Gu³ | Hongwei An⁴ | Zheyi Zhou⁴ | Dong Zheng⁵ | Zhanhang Wang⁶ | Zehuai Wen² | Hai-Ying Shen⁷ | Qi Wang² | Honghao Wang¹

¹Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
²Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China
³Department of Encephalopathy, Hainan Provincial Hospital of Traditional Chinese Medicine, Haikou, China
⁴Department of Neurology, Liuzhou Traditional Chinese Medical Hospital, Liuzhou, China
⁵Department of Neurology, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China
⁶Department of Neurology, 999 Brain Hospital, Guangzhou, China
⁷RS Dow Neurobiology Laboratories, Legacy Research Institute, Portland, Oregon

Abstract

Background: Neurofilaments (Nf) are a series of highly specific scaffolding proteins of neurons. Neurofilament light chains (Nf-L) and the heavy one (Nf-H) are subunits of Nf, and they are recognized as potent productions of neural damage. The concentrations of Nf aggrandized significantly in neurological disease including neuromyelitis optica, multiple sclerosis, and Alzheimer's disease. However, whether Nf in cerebrospinal fluid (CSF) elevated in anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is unclear. Here, we aimed to detect whether CSF Nf is altered in NMDAR and whether changes in CSF Nf can serve as an objective and effective biomarker to evaluate disease severity and prognosis.

Methods: We collected 24 anti-NMDAR encephalitis patients, 11 viral meningoencephalitis/encephalitis (VM) patients, and 21 controls in this study. CSF Nf-L, Nf-H, and cytokine levels (IL-1β, IL-6, and IL-17A) were determined by enzyme-linked immunosorbent assay (ELISA) and compared between groups. We evaluated patients' clinical outcomes or prognosis according to modified Rankin scale (mRS) score.

Results: Compared with controls, both CSF Nf-L and Nf-H levels were significantly increased in anti-NMDAR encephalitis patients. While compared with VM patients, only Nf-L were increased in anti-NMDAR encephalitis patients. Moreover, CSF Nf-L were positively correlated with concentration of cytokines (IL-1β, IL-17A) and mRS scores in anti-NMDAR encephalitis patients. After treatment, both CSF Nf-L and Nf-H levels decreased. Furthermore, the Nf-L during follow-up positively correlated with 3-month mRS scores, and ΔNf-L positively correlated with ΔmRS.

Correspondence

Honghao Wang, Department of Neurology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, Guangdong 510515, China. Email: wang_whh@163.com

Qi Wang, Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China. Email: wangqiguzcme.edu.cn

Hai-Ying Shen, Department of Neurobiology, Legacy Research Institute, 1225 NE 2nd Ave, Portland, OR 97232, USA. Email: hshen@downeurobiology.org

Funding information

This work is funded by National Natural Science Foundation of China (grant number 81673950); Natural Science Foundation of Guangdong Province of China (grant number 2016A030313828); Guangdong Provincial Science and Technology plan Projects (grant numbers 2016A020215101 and 2017A020215182); Liuzhou "A 1000 Talent Project in the New Century" Special Funds (grant number 2209.06-00210); and the Science and Technology Innovation Ability and the Condition of Construction Project of Liuzhou (grant number 2014J030407).
1 | INTRODUCTION

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is commonly known as an autoimmune disease with characterized symptoms as psychosis, epilepsy, autonomic nervous system in dysfunction, and various disturbances in movement (Dalmau, Lancaster, Martinez-Hernandez, Rosenfeld, & Balice-Gordon, 2011; Kayser, Titulaer, Gresa-Arribas, & Dalmau, 2013). The concept of anti-NMDAR encephalitis associated with ovarian teratoma was first recorded in 2007; twelve women with a series of neuropsychiatric syndrome were detected to have autoantibodies binding to glutamate receptors (type NMDA) (Dalmau et al., 2007). This clinical phenotype was due to internalization of NMDARs mediated by anti-NMDAR antibodies. However, anti-NMDAR encephalitis was subsequently found in patients without tumors. Thus, it is possible that such antibodies could arise from immunologic triggers else instead of tumor (Dalmau et al., 2008). Though B and T leukocytes were proposed to exert in anti-NMDAR encephalitis, further research is needed to illuminate the underlying immunopathogenesis of this disease (Tuzun et al., 2009).

Neurofilaments (NF) are a series of highly specific scaffolding proteins of neurons. They are located in axons and contain three structurally similar subunits named as NF-heavy chain (NF-H), NF-medium chain (NF-M), and NF-light chains (NF-L) with molecular weight of 200, 150, and 68 kDa, respectively (Petzold, 2005). The disruption of NF occurs under the conditions of neurodegeneration or neuronal cell death (Gaiottino et al., 2013; Petzold, 2005); subsequently, NF increased in cerebrospinal fluid (CSF) or serum (Petzold et al., 2011; Zetterberg et al., 2013). NF-L are major structural subunits in myelinated axons, and they are essential for the formation of heteropolymer by copolymerization with two other subunits, NF-M and NF-H (Geisler & Weber, 1981; Lee et al., 1993). These subunits play a significant role in maintaining axonal caliber and conduction velocity. Deficiency of NF-L could influence the morphological integrity of axon and effective conduction of nerve impulses. Absence of NF-H subunit does not greatly reduce the neurofilaments in peripheral and sensory axons, but it is vital to the survival of motor and sensory axons. Increased NF-L levels were found in neurological diseases including human spinal cord injury (Kuhle, Gaiottino, et al., 2015), multiple sclerosis, and various neurodegenerative diseases (Kuhle, Disanto, et al., 2015; Petzold, 2005; Sjogren et al., 2000). Likewise, NF-H have been reported to increase in acute ischemic stroke (Singh et al., 2011). The levels of NF-L and NF-H in CSF are taken for more indicative of brain pathology than those in serum. However, whether CSF NF-L and NF-H elevated in anti-NMDAR encephalitis patients remains undefined. CD4⁺ T cells take part in pathogenesis and development in some autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis (Damsker, Hansen, & Caspi, 2010). In anti-NMDAR encephalitis, the immune response is probably triggered initially by tumor, virus, or uncertain precipitating factors else and subsequently activated and amplified in the CNS (Dalmau et al., 2011; Tuzun et al., 2009; Zandi et al., 2015). Here, we measured the levels of cytokines that are associated with the function of these cells, including IL-1β, IL-6, and IL-17A. Previously, we have reported other high expression inflammatory cytokines in serum or CSF in anti-NMDAR encephalitis patients (Ai et al., 2018; Patakas et al., 2012).

We aimed to investigate whether NF-L or NF-H levels were altered in anti-NMDAR encephalitis patients and to further explore whether the NF proteins were associated with disease severity, clinical outcomes, and prognosis. Considering that another major encephalitis in central nervous system is caused by virus, we compared these indicators in anti-NMDAR encephalitis patients with patients in control group and patients with viral meningoencephalitis/encephalitis (VM).

2 | MATERIALS AND METHOD

2.1 | Patients groups and control group

Our study included three groups—anti-NMDAR encephalitis group (24 patients); viral meningoencephalitis/encephalitis (VM) group (11 patients); and control group (21 patients). All of them were selected from the Department of Neurology, Nanfang Hospital of Southern Medical University. We adopted the revised criteria defined by Graus et al. in 2016 to elect the anti-NMDAR encephalitis patients (Graus et al., 2016). Viral meningoencephalitis/encephalitis is caused by a variety of viruses and belongs to the category of etiological diagnosis. Herpes simplex virus, adenovirus, and enterovirus are common pathogens. The diagnostic criteria of the viral meningoencephalitis are as follows: (a) symptoms of acute onset of systemic infection poisoning (fever, headache); (b) meningeal irritation sign; (c) CSF lymphocytes are moderately elevated, leukocyte count 10–300 (×10⁶/L), glucose 2.5–3.5 mM, protein < 0.8 g/L; (d) cerebrospinal fluid pathology, no evidence of bacterial (including tuberculosis and mycosis) infection was found; and (e) exclude other diseases. The diagnostic criteria of the viral encephalitis are as follows: (a) prodrome of viral infection.

Conclusions: Briefly, CSF NF-L levels notably increased in anti-NMDAR encephalitis patients in acute phase and positively correlated with disease severity. It could be considered as a useful indicator for clinical outcomes and prognosis.

KEYWORDS

anti-NMDAR encephalitis, cerebrospinal fluid, cytokine, modified Rankin scale, neurofilament heavy subunit, neurofilament light subunit
Subsequently, high fever, severe headache, nausea, vomiting, and disturbance of consciousness often accompanied by focal nervous system positioning signs and convulsions (convulsions can be the first symptoms); (b) clinically, there are signs of brain parenchyma damage caused by virus infection; (c) cerebrospinal fluid showed no inflammatory changes, and no evidence of bacterial (including tuberculosis and mycosis) infection was found; (d) the EEG showed diffuse abnormality (some could be focal), and no sign of space occupying lesion in CT or MR; (e) serum antibody titer increased significantly. Patients in VM group were identified according to criteria above, and they were excluded from other types of CNS diseases. The age- and sex-matched control individuals were patients with other neurological disorders, including movement disorders and cerebrovascular diseases, among whose clinical symptoms and laboratory examinations supported neither for a diagnosis of anti-NMDAR encephalitis nor viral meningitis/encephalitis. Anti-NMDAR antibodies were found to be positive in all CSF of the anti-NMDAR encephalitis patients selected at the time of diagnosis by cell-based analysis. We assessed their dominating clinical outcomes and prognosis on the ground of the modified Rankin scale (mRS).

2.2 | Ethics statement

All procedures were carried out with the adequate understanding and written consent of the participants as well as the approval of the Ethics Committee of the Nanfang Hospital, Southern Medical University.

2.3 | Biochemical assays

All of the CSF samples were collected by the time of diagnoses and reserved in the refrigerator at −80°C until we performed the assays. The Nf-L (IBL) and phosphorylated neurofilament (pNf-H; Biovendor) were quantified by Sandwich ELISA immunoassay assay according to the manufacturer’s instructions. The concentrations of IL-1β, IL-6, and IL-17A were determined by enzyme-linked immunosorbent assay (Bender MedSystems GmbH Campus Vienna).

2.4 | Follow-up evaluations

Nine of the 24 anti-NMDAR encephalitis patients were re-examined those same parameters in our hospital in 3 months later after onset, as routine follow-up. The other 15 patients did not come back to our hospital or rejected the repeated lumbar puncture examination. Follow-up patients’ neurological outcomes were assessed two times by mRS when they got the worst conditions (Max mRS score) as well as 3 months after ictus (3 months mRS score). \( \Delta \text{Nf-L} = \text{Nf-L (acute stage)} - \text{Nf-L (follow-up)} \), \( \Delta \text{IL-1β} \), \( \Delta \text{IL-6} \), \( \Delta \text{IL-17A} \), and \( \Delta \text{mRS} \) were similar to this calculation.

2.5 | Statistical analysis of data

We carried out all statistical analysis by SPSS version 20.0 (IBM Corp). CSF Nf-L, pNf-H, IL-1β, IL-6, IL-17A, and ages were presented in the form of the mean ± standard deviation (SD) for the data distributed normally. The information of mRS scores was demonstrated by medians (min, max) when the data were not normally distributed. One-way ANOVA was adopted to distinguish the differences about Nf-L, pNf-H, and cytokines between groups, paired sample t test to analyze those parameters of nine follow-up anti-NMDAR encephalitis patients during acute stage and follow-up. Pearson test was used to assess the correlations between Nf and cytokines, while Spearman’s correlations to analyze the Nf and mRS scores. We decided the sample size by the statistical sample size formula \( n = \left\lfloor \left( \mu_\alpha + \mu_\beta \right)^2 / (1 + 1/K) \right\rfloor / \sigma^2 \) using the online sample size statistics tool (http://powerandsamplesize.com/). A p value < 0.05 was viewed as an indication of statistical significance in the actual study.

3 | RESULTS

3.1 | Clinical characteristics and demographic data of participants

The baseline characteristics of the anti-NMDAR encephalitis group, VM group, and controls were shown (Table 1). The mean ages (years) of the anti-NMDAR encephalitis patients were 34.02 ± 18.71, the VM group 33.82 ± 16.38, and the control group 36.48 ± 15.46. The median Max mRS score and 3 months mRS score of the anti-NMDAR encephalitis group was 4.0 (range 3.0–5.0) and 3.0 (range 1.0–5.0), respectively. Three of the 24 anti-NMDAR encephalitis patients (12.5%) had ovarian teratoma. There were no statistical significances in age and sex distribution among the three groups.

3.2 | Nf-L, pNf-H, and cytokines in patients group and control group

Means of CSF Nf-L were 3,292.63 pg/ml for anti-NMDAR encephalitis group, 1,662.27 pg/ml for VM group, and 1,270.57 pg/ml for control group. Means of CSF pNf-H for anti-NMDAR encephalitis patients, VM patients, and controls were 1,824.63, 1,411.09, and 1,182.57 pg/ml, respectively. Compared with controls, Nf-L (\( p < 0.0001 \)) and pNf-H (\( p = 0.004 \)) in anti-NMDAR encephalitis group were increased, while both Nf-L and pNf-H levels in VM group showed no statistical differences. CSF Nf-L level but not pNf-H showed statistical differences between the VM group and patients with anti-NMDAR encephalitis (Figure 1a,b). Concentrations of IL-1β, IL-6, and IL-17A dramatically increased in anti-NMDAR encephalitis group compared with controls (\( p < 0.0001 \)) (Table 1).

3.3 | Positive correlations between Nf, cytokines, and mRS score

An analysis of relationships between Nf, cytokines, and mRS score was conducted (Table 2). In anti-NMDAR encephalitis group, Nf-L
were positively correlated with IL-1β (p = 0.017), IL-17A (p = 0.0001), and Max mRS scores (p = 0.020), respectively, while pNF-H had no correlations with any cytokines or mRS scores in both groups (data not shown).

### 3.4 | Follow-up measurement of 9 NMDAR patients

As our results pointed out the relevance between Nf-L and disease severity (mRS score) in anti-NMDAR encephalitis patients in the acute phase, we further assessed whether CSF Nf, cytokines, and mRS score altered after therapy. Nine follow-up anti-NMDAR encephalitis patients (female:male: 6:3) received the remeasurement of these indexes. After treatment, CSF Nf-L, pNF-H, IL-1β, IL-6, IL-17A, and mRS score decreased (Figure 2a-f). In addition, NF-L during follow-up were associated with 3 months mRS scores (Figure 3a), and the ΔNF-L is positively correlated with the ΔmRS (Figure 3c), while no such relations were found in NF-H (Figure 3b,d). The decrease of all cytokines has no relation with ΔNF-L or ΔNF-H (Table 3).

| TABLE 1 Clinical features of patients and control individuals |
|---------------------------------------------------------------|
| Gender, female/male                                           |
| anti-NMDAR encephalitis (n = 24)                              |
| VM (n = 11)                                                   |
| Controls (n = 21)                                             |
| Age (years)                                                  |
| 34.02 ± 18.71                                                 |
| 33.82 ± 16.38                                                 |
| 36.48 ± 15.46                                                 |
| CSF IL-1β (pg/ml, mean ± SD)                                 |
| 5.73 ± 3.50 ****                                              |
| 3.74 ± 1.98                                                   |
| 1.84 ± 0.94 ****                                              |
| CSF IL-6 (pg/ml, mean ± SD)                                  |
| 10.21 ± 5.78 ****                                             |
| 7.20 ± 6.52                                                   |
| 3.81 ± 1.47 ****                                              |
| CSF IL-17A (pg/ml, mean ± SD)                                |
| 10.29 ± 5.42 ****                                             |
| 4.62 ± 1.15                                                   |
| 2.82 ± 1.67 ****                                              |
| Symptom (n, %)                                                |
| Prodromal symptoms (fever)                                   |
| 13 (54.2)                                                    |
| 8 (72.7)                                                      |
| Disorder of behavior and cognition                            |
| 21 (87.5)                                                    |
| 3 (27.3)                                                      |
| Memory deficits                                              |
| 12 (50.0)                                                    |
| 1 (9.0)                                                       |
| Speech disturbances                                          |
| 14 (58.3)                                                    |
| 1 (9.0)                                                       |
| Seizures                                                     |
| 18 (75.0)                                                    |
| 3 (27.3)                                                      |
| Movement disorders                                           |
| 11 (45.8)                                                    |
| 2 (18.2)                                                      |
| Loss of consciousness                                        |
| 15 (62.5)                                                    |
| 6 (54.5)                                                      |
| Autonomic nerve disorder                                     |
| 10 (41.7)                                                    |
| 0 (0.0)                                                       |
| Hypopnea                                                     |
| 8 (33.3)                                                      |
| 2 (18.2)                                                      |
| Anti-NMDAR antibody                                          |
| 24                                                           |
| 0                                                            |
| Max mRS score (median, range)                                 |
| 4.0 (3.0–5.0)                                                 |
| 3.0 (1.0–5.0)                                                 |

Abbreviations: anti-NMDAR encephalitis, anti-N-methyl-D-aspartate receptor encephalitis; CSF, cerebrospinal fluid; EEG, electroencephalogram; VM, viral meningoencephalitis/encephalitis.

* p < 0.05.
** p < 0.01.
*** p < 0.001.
**** p < 0.0001.
Our research discovered that CSF Nf-L and pNf-H increased in anti-NMDAR encephalitis patients compared with controls. After treatment, CSF Nf-L and pNf-H decreased. While compared with VM patients, only CSF Nf-L statistically increased in anti-NMDAR encephalitis patients. Additionally, in anti-NMDAR encephalitis patients, Nf-L were relevant to cytokines (IL-1β, IL-17A) and mRS scores, and ΔmRS is positively correlated with ΔNf-L.

NF release resulting from neuronal damage (Gaiottino et al., 2013). Whereafter, Nf-L concentrations elevate in the CSF and serum (Petzold et al., 2011; Zetterberg et al., 2013). In animal models, neurofilaments were verified to maintain the speed of signal transduction in nerve and the axonal caliber. Nf-L knockout mice seemed to have smaller axon diameter (twofold to threefold reduction) and slower conduction speed (50% decrease) (Julien & Mushynski, 1998), which can lead to neurological dysfunctions. Besides, Nf-L-targeted disruption mice showed the feature of neurodegenerative diseases—protein aggregation in motoneurons (Li et al., 2006). Additionally, Axelsson et al have propounded the feasibility that Nf-L polymerize by itself leading to protein accumulation and aggregate formation, which may concern with CNS diseases (Axelsson et al., 2014). Thus, Nf-L was related with neurological diseases. In this study, we discovered that CSF Nf-L were higher in anti-NMDAR encephalitis patients and related with mRS scores, which implied the axonal injuries and Nf-L accumulation in CSF. Similarly, increased Nf-L has been discovered in neuromyelitis optica and multiple sclerosis (Madeddu et al., 2013; Wang et al., 2013). Thus, Nf-L may be related with autoimmune encephalitis. Compared to Nf-L, Nf-H were found in higher level in

### TABLE 2 Relationship between CSF Nf levels and cytokines or mRS scores in NMDAR patients

| Nf-L | p Value | r Value |
|------|---------|---------|
| CSF IL-1β | 0.017 | 0.436 |
| CSF IL-6 | 0.124 | 0.245 |
| CSF IL-17A | 0.0001 | 0.676 |
| Max mRS scores | 0.020 | 0.422 |

| pNf-H | p Value | r Value |
|------|---------|---------|
| CSF IL-1β | 0.065 | 0.371 |
| CSF IL-6 | 0.088 | 0.268 |
| CSF IL-17A | 0.167 | 0.206 |
| Max mRS scores | 0.219 | 0.166 |

Abbreviation: mRS, modified Rankin scale.

4 | DISCUSSION

Follow-up evaluation of clinical parameters in anti-NMDAR encephalitis. CSF Nf-L (a) and pNf-H (b) levels were significantly decreased when followed up (Nf-L, p = 0.009; Nf-H, p = 0.004). IL-1β (c) IL-6 (d), IL-17A (e), and mRS scores (f) were significantly decreased when followed up (IL-1β, p = 0.002; IL-6, p = 0.007; IL-17A, p < 0.0001; mRS scores, p = 0.017)
anti-NMDAR encephalitis patients only when compared with control group but not with VM group. The breakdown of Nf depends on protease digestion, and susceptibility of Nf to protease digestion decreases with increase of phosphorylation. Nf-H is the most extensively phosphorylated protein of the human brain and pNf-H was considered to show lower activities to proteolytic enzymes (Goldstein, Sternberger, & Sternberger, 1987). Nf-L are more susceptible to protease activity than Nf-H. What’s more, Petzold A had proposed that Nf-L are more sensitive to be detected than the heavy chain (Petzold, 2005). By comparison, Nf-L are more suitable to mark brain damage and reflect the severity and outcomes of disease.

Immune B cells and T cells are indispensable regulators and effectors in immune responses to the formation and development of anti-NMDAR encephalitis (Camdessanche et al., 2011; Chen et al., 2018; Hachiya et al., 2013; Peng et al., 2019). However, how they enter the CNS compartment or the blood–brain barrier is undefined. IL-1β has been taken for a contributing factor in either autoinflammatory or autoimmune diseases and the induction of fever (Dinarello, 2011; Horai et al., 1998; Sims & Smith, 2010). It was found to damage cognitive abilities in Alzheimer’s disease and influence the Th17 differentiation in naïve T cells of mouse and human (Acosta-Rodriguez, Napolitani, Lanzavecchia, & Sallusto, 2007; Bossu et al., 2007; Chung et al., 2009). Besides, inflammation and ischemic brain injury could be alleviated by IL-1 receptor antagonist treatment in model rats (Pradillo et al., 2012). Elevated IL-6 has been reported in autoimmune diseases like neuromyelitis optica (Uzawa et al., 2010). Th17 cells were demonstrated to increase in multiple sclerosis (Keibir et al., 2009). IL-17A, a proinflammatory cytokine derived from Th17 cells, was reported to increase in anti-NMDAR encephalitis patients (Liu et al., 2018). Consistently, our research revealed the increase of IL-1β, IL-6, and IL-17A in anti-NMDAR encephalitis patients compared with control. Moreover, Nf-L positively correlated with cytokines (IL-1β and IL-17A) and mRS score, suggesting the possibility that Nf-L concerned with inflammation reaction and the prognosis and severity in anti-NMDAR encephalitis.

Interestingly, our results proved that after treatment, CSF Nf-L, Nf-H, cytokines, and mRS scores observably decreased in anti-NMDAR encephalitis, indicating the effectiveness of treatment. Furthermore, the ΔmRS is positively correlated with ΔNf-L. In other words, after treatment, the more the Nf-L declined, the more obvious improvement of disease showed. It further proved that Nf-L related with the disease severity.

We speculated that the decrease of CSF Nf-L was potentially due to the catabatic inflammatory injuries in CNS after getting treatment. Alternatively, descending concentration of CSF Nf-L could protect neuronal cell from inflammatory responses and injury. Though the underlying immunologic mechanism why Nf-L altered is indeterminate, Nf-L concentrations could play an important role in reflecting outcomes and prognosis of anti-NMDAR encephalitis. Whether there is an effective way to repair neurofilament protein to treat cerebral lesion remained to be confirmed.

**FIGURE 3** Correlation between Nf and mRS scores during follow-up. There was a positive correlation between Nf-L during follow-up and 3-month mRS (a) (p = 0.009), ΔNf-L, and ΔmRS (c) (p = 0.038), respectively. There was no correlation between neither Nf-H during follow-up and 3-month mRS (b) (p = 0.234), nor ΔmRS and the ΔpNf-H (d) (p = 0.480)
5 | CONCLUSION

Briefly, our study discovered that anti-NMDAR encephalitis patients get a noteworthy higher CSF NF-L and pNF-H levels. And the increase of NF-L was positively related to disease severity, supporting that NF-L are more meaningful to reflect the potential pathogenesis of this autoimmune disease and indicate the clinical outcomes or prognosis. It would shed a new light to access disease severity, efficacy, and prognosis by using a biomarker in anti-NMDAR encephalitis.

ACKNOWLEDGMENTS

Not applicable.

CONFLICT OF INTEREST

None.

DATA ACCESSIBILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Honghao Wang https://orcid.org/0000-0002-1215-6219

REFERENCES

Acosta-Rodriguez, E. V., Napolitani, G., Lanzavecchia, A. & Sallusto, F. (2007). Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nature Immunology, 8, 942–949.

Ai, P., Zhang, X., Xie, Z., Liu, G., Liu, X., Pan, S., & Wang, H. (2018). The HMGB1 is increased in CSF of patients with an Anti-NMDAR encephalitis. Acta Neurologica Scandinavica, 137(2), 277–282. https://doi.org/10.1111/anे.12850

Axelsson, M., Malmström, C., Gunnarsson, M., Zetterberg, H., Sundström, P., Lycke, J., & Svenningsson, A. (2014). Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Multiple Sclerosis Journal, 20(1), 43–50. https://doi.org/10.1177/1352458613490544

Bouss, P., Ciaramella, A., Moro, M. L., Bellincampi, L., Bernardini, S., Federici, G., ... Spalletta, G. (2007). Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer’s disease. Journal of Neurology, Neurosurgery, and Psychiatry, 78(8), 807–811. https://doi.org/10.1136/jnnp.2006.103242

Camdessanché, J.-P., Streichenberger, N., Cavillon, G., Rogemond, V., Jousserand, G., Honnorat, J., ... Antoine, J.-C. (2011). Brain immunohistopathological study in a patient with anti-NMDAR encephalitis. European Journal of Neurology, 18(6), 929–931. https://doi.org/10.1111/j.1468-1331.2010.03180.x

Chen, J., Ding, Y., Zheng, D., Wang, Z., Pan, S., Ji, T., ... Wang, H. (2018). Elevation of YKL-40 in the CSF of anti-NMDAR encephalitis patients is associated with poor prognosis. Frontiers in Neurology, 9, 727. https://doi.org/10.3389/fneur.2018.00727

Chung, Y., Chang, S. H., Martinez, G. J., Yang, X. O., Nurieva, R., Kang, H. S., ... Dong, C. (2009). Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity, 30(4), 576–587. https://doi.org/10.1016/j.immuni.2009.02.007

Dalmau, J., Balice-Gordon, R., Benseler, S., Bien, C. G., Cellucci, T., ... Tuzun, E., Wu, H.-Y., Masjuan, J., Rossi, J. E., ... Lynch, D. R. (2007). Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Annals of Neurology 61, 25–36.

Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., ... Lynch, D. R. (2008). Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. The Lancet Neurology, 7(12), 1091–1098. https://doi.org/10.1016/S1474-4422(08)70224-2

Dalmau, J., Lancaster, E., Martinez-Hernandez, E., Rosenfeld, M. R., & Balice-Gordon, R. (2011). Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. The Lancet Neurology, 10(1), 63–74. https://doi.org/10.1016/S1474-4422(10)70253-2

Damsker, J. M., Hansen, A. M., & Caspi, R. R. (2010). Th1 and Th17 cells. Annals of the New York Academy of Sciences, 1183(1), 211–221. https://doi.org/10.1111/j.1749-6632.2009.05133.x

Dinarello, C. A. (2011). Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood, 117(14), 3720–3732.

Gaiottino, J., Norgren, N., Dobson, R., Topping, J., Nissim, A., Malaspina, A., ... Kuhle, J. (2013). Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One, 8(9), e75091. https://doi.org/10.1371/journal.pone.0075091

Geisler, N., & Weber, K. (1981). Self-assembly in vitro of the 68,000 molecular weight component of the mammalian neurofilament triplet proteins into intermediate-sized filaments. Journal of Molecular Biology 151, 565–571.

Goldstein, M. E., Sternberger, N. H., & Sternberger, L. A. (1987). Phosphorylation protects neurofilaments against proteolysis. Journal of Neuroimmunology, 14(2), 149–160. https://doi.org/10.1016/0165-5728(87)90049-X

Graus, F., Tutilaer, M. J., Balu, R., Benseler, S., Bien, C. G., Cellucci, T., ... Dalmau, J. (2016). A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology, 15(4), 391–404. https://doi.org/10.1016/S1474-4422(15)00401-9

Hachiya, Y., Uruha, A., Kasai-Yoshida, E., Shimoda, K., Satoh-Shirai, I., Kumada, S., ... Sakuma, H. (2013). Rituximab ameliorates anti-N-methyl-D-aspartate receptor encephalitis by removal of short-lived plasmablasts. Journal of Neuroimmunology, 265(1–2), 128–130. https://doi.org/10.1016/j.jneuroim.2013.09.017

Horai, R., Asano, M., Sudo, K., Kanuka, H., Suzuki, M., Nishihara, M., ... Ikawara, Y. (1998). Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. The Journal of Experimental Medicine 187(9), 1463–1475.

Julien, J. P., & Mushynsky, W. E. (1998). Neurofilaments in health and disease. Progress in Nucleic Acid Research and Molecular Biology, 61, 1–23.

Kaysar, M. S., Tutilaer, M. J., Gresa-Arribas, N., & Dalmau, J. (2013). Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurology, 70(9), 1133–1139.

Kebir, H., Ifergan, I., Alvarez, J. I., Bernard, M., Poirier, J., Arbour, N., ... Prat, A. (2009). Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Annals of Neurology, 66(3), 390–402.

Kuhle, J., Disanto, G., Lorschieder, J., Sittes, T., Chen, Y., Dahlke, F., ... Kappos, L. (2015). Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 84(16), 1639–1643.

Kuhle, J., Gaiottino, J., Leppert, D., Petzold, A., Bestwick, J. P., Malaspina, A., ... Casha, S. (2015). Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. Journal of Neurology, Neurosurgery and Psychiatry, 86(3), 273–279. https://doi.org/10.1136/jnnp-2013-307454
Lee, M. K., Xu, Z., Wong, P. C., & Cleveland, D. W. (1993). Neurofilaments are obligate heteropolymers in vivo. *Journal of Cellular Biology* 122(6), 1337-1350.

Li, Z. H., Lu, J., Tay, S. S., Wu, Y. J., Strong, M. J., & He, B. P. (2006). Mice with targeted disruption of neurofilament light subunit display formation of protein aggregation in motorneurons and downregulation of complement receptor type 3 alpha subunit in microglia in the spinal cord at their earlier age: A possible feature in pre-clinical development of neurodegenerative diseases. *Brain Research*, 1113(1), 200–209.

Liu, B., Xie, Z., Liu, G., Gu, Y., Pan, S., & Wang, H. (2018). Elevated neuron-specific enolase and S100 calcium-binding protein B concentrations in cerebrospinal fluid of patients with anti-N-methyl-d-aspartate receptor encephalitis. *Clinica Chimica Acta*, 480, 79–83.

Madeddu, R., Farace, C., Tolu, P., Solinas, G., Asara, Y., Sotgiu, M. A., ... Montella, A. (2013). Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis. *Neurological Sciences* 34(2), 181-186.

Patakas, A., Benson, R. A., Withers, D. R., Conigliaro, P., McInnes, I. B., Brewer, J. M., & Garside, P. (2012). Th17 effector cells support B cell responses outside of germinal centres. *PloS One*, 7(11), e49715. https://doi.org/10.1371/journal.pone.0049715

Peng, Y., Zheng, D., Zhang, X., Pan, S., Ji, T., Zhang, J., ... Wang, H. H. (2019). Cell-free mitochondrial DNA in the CSF: A potential prognostic biomarker of anti-nmdar encephalitis. *Frontiers in Immunology*, 10, 103. https://doi.org/10.3389/fimmu.2019.00103

Petzold, A. (2005). Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss. *Journal of the Neurological Sciences*, 233(1-2), 183–198. https://doi.org/10.1016/j.jns.2005.03.015

Petzold, A., Tisdall, M. M., Girbes, A. R., Martinian, L., Thom, M., ... Smith, M. (2011). In vivo monitoring of neuronal loss in traumatic brain injury: A microdialysis study. *Brain* 134(Pt 2), 464–483.

Pradillo, J. M., Denes, A., Greenhalgh, A. D., Boutin, H., Drake, C., McColl, B. W., ... Allan, S. M. (2012). Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. *Journal of Cerebral Blood Flow and Metabolism*, 32(9), 1810–1819.

Sims, J. E., & Smith, D. E. (2010). The IL-1 family: Regulators of immunity. *Nature Reviews Immunology*, 10(2), 89–102.

Singh, P., Yan, J., Hull, R., Read, S., O’Sullivan, J., Henderson, R. D., ... McCombe, P. A. (2011). Levels of phosphorylated axonal neurofilament subunit H (pNfH) are increased in acute ischemic stroke. *Journal of the Neurological Sciences*, 304(1-2), 117-121. https://doi.org/10.1016/j.jns.2011.01.025

Sjogren, M., Rosengren, L., Minthon, L., Davidsson, P., Blennow, K., & Wallin, A. (2000). Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. *Neurology* 54(10), 1960–1964.

Tuzun, E., Zhou, L., Baehring, J. M., Bannykh, S., Rosenfeld, M. R., & Dalmau, J. (2009). Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. *Acta Neuropathologica*, 118(6), 737–743. https://doi.org/10.1007/s00401-009-0582-4

Uzawa, A., Mori, M., Arai, K., Sato, Y., Hayakawa, S., Masuda, S., ... Kuwabara, S. (2010). Cytokine and chemokine profiles in neuromyelitis optica: Significance of interleukin-6. *Multiple Sclerosis Journal*, 16(12), 1443–1452. https://doi.org/10.1177/1352458510379247.

Wang, H., Wang, C., Qiu, W., Lu, Z., Hu, X., & Wang, K. (2013). Cerebrospinal fluid light and heavy neurofilaments in neuromyelitis optica. *Neurochemistry International*, 63(8), 805–808. https://doi.org/10.1016/j.neuint.2013.10.008

Zandi, M. S., Paterson, R. W., Ellul, M. A., Jacobson, L., Al-Diwani, A., Jones, J. L., ... Vincent, A. (2015). Clinical relevance of serum antibodies to extracellular N-methyl-d-aspartate receptor epitopes. *Journal of Neurology, Neurosurgery and Psychiatry*, 86(7), 708–713.

Zetterberg, H., Smith, D. H., & Blennow, K. (2013). Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. *Nature Reviews Neurology* 9, 201–210.

How to cite this article: Li J, Gu Y, An H, et al. Cerebrospinal fluid light and heavy neurofilament level increased in anti-N-methyl-d-aspartate receptor encephalitis. *Brain Behav*. 2019;9:e01354. https://doi.org/10.1002/brb3.1354